+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the use of pemigatinib for adults with advanced or metastatic pancreatic cancer that has spread locally or to distant parts of the body. This study focuses on patients whose cancer has specific abnormal changes in the FGFR gene, which can promote cancer growth. The goal is to see if pemigatinib can block these abnormal genes to stop tumor growth and improve quality of life. Participants take pemigatinib orally once daily for 14 days in each 21-day cycle, continuing as long as the cancer does not worsen or side effects are manageable. During the study, patients undergo blood tests, CT andor MRI scans, and optical coherence tomography OCT. Additional scans like whole body bone scans and eye exams may be performed if needed. After treatment, patients are followed up 30 days later and then every 4 months for one year. Throughout the study, researchers assess tumor response using imaging and blood tests, including monitoring cell-free DNA to track response and resistance. They measure overall response rate up to 24 months and evaluate progression-free survival, disease control, overall survival, and side effects up to 12 months. Safety and tolerability are closely monitored, and patients overall health and treatment effects are regularly checked to understand the impact of pemigatinib.

Age: 18Years +All GendersPhase 2
109 locations
E

Actively Recruiting

Healthy Volunteer

Autism spectrum disorder ASD affects communication, social interaction, and behavior in children. Early identification of ASD helps families access support sooner. This study evaluates the APS Detect12 handheld pupillometer, a device that measures pupil responses to light, to help screen for ASD in children aged 2 to 4 during routine pediatric healthcare visits. Researchers aim to compare the devices screening results with standard clinical ASD assessments to determine its accuracy. The study involves using the APS Detect device to measure pupillary light reflex in children, generating an Autism Pupil Screening APS score to estimate ASD risk. Participants undergo standard clinical evaluations for ASD diagnosis alongside the pupillometer assessments. A precision sub-study will assess the consistency of APS scores when measured by different healthcare professionals using multiple assessments. Participants will attend routine pediatric visits where the device and standard screening tools are used. Researchers will collect data including APS scores and diagnostic outcomes to evaluate device performance, safety, and suitability for clinical use. The primary outcome measures sensitivity and specificity of the APS score in classifying ASD, with additional measures including predictive values. The study period from enrollment to final testing visits lasts 14 to 30 days.

Age: 24Months - 60MonthsAll Genders
4 locations